Cisatracurium besilate

Drug Profile

Cisatracurium besilate

Alternative Names: 51W; 51W89; Nimbex; Nombex

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Abbott Laboratories; GlaxoSmithKline
  • Class Benzylisoquinolines; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Muscle hypertonia

Most Recent Events

  • 12 Sep 2016 Aspen acquires cisatracurium besilate from GlaxoSmithKline
  • 12 Aug 2016 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top